Trending Now: Cancer Stem Cells (CSCs) Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026| Janssen, Qiagen, Advanced Cell…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Cancer Stem Cells (CSCs) Market Research Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Cancer Stem Cells (CSCs) market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Cancer Stem Cells (CSCs) market include: , Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2010378/global-cancer-stem-cells-cscs-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Cancer Stem Cells (CSCs) market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Cancer Stem Cells (CSCs) Market Segment By Type:

CellSearch Others

Global Cancer Stem Cells (CSCs) Market Segment By Application:

Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cancer Stem Cells (CSCs) market.

Key companies operating in the global Cancer Stem Cells (CSCs) market include , Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/2010378/global-cancer-stem-cells-cscs-market

TOC

1 Cancer Stem Cells (CSCs) Market Overview 1.1 Product Overview and Scope of Cancer Stem Cells (CSCs) 1.2 Cancer Stem Cells (CSCs) Segment by Type 1.2.1 Global Cancer Stem Cells (CSCs) Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 CellSearch 1.2.3 Others 1.3 Cancer Stem Cells (CSCs) Segment by Application 1.3.1 Cancer Stem Cells (CSCs) Sales Comparison by Application: 2020 VS 2026 1.3.2 Breast Cancer Diagnosis and Treatment 1.3.3 Prostate Cancer Diagnosis and Treatment 1.3.4 Colorectal Cancer Diagnosis and Treatment 1.3.5 Lung Cancer Diagnosis and Treatment 1.3.6 Other Cancers Diagnosis and Treatment 1.4 Global Cancer Stem Cells (CSCs) Market Size Estimates and Forecasts 1.4.1 Global Cancer Stem Cells (CSCs) Revenue 2015-2026 1.4.2 Global Cancer Stem Cells (CSCs) Sales 2015-2026 1.4.3 Cancer Stem Cells (CSCs) Market Size by Region: 2020 Versus 2026 1.5 Cancer Stem Cells (CSCs) Industry 1.6 Cancer Stem Cells (CSCs) Market Trends 2 Global Cancer Stem Cells (CSCs) Market Competition by Manufacturers 2.1 Global Cancer Stem Cells (CSCs) Sales Market Share by Manufacturers (2015-2020) 2.2 Global Cancer Stem Cells (CSCs) Revenue Share by Manufacturers (2015-2020) 2.3 Global Cancer Stem Cells (CSCs) Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Cancer Stem Cells (CSCs) Manufacturing Sites, Area Served, Product Type 2.5 Cancer Stem Cells (CSCs) Market Competitive Situation and Trends 2.5.1 Cancer Stem Cells (CSCs) Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Cancer Stem Cells (CSCs) Players (Opinion Leaders) 3 Cancer Stem Cells (CSCs) Retrospective Market Scenario by Region 3.1 Global Cancer Stem Cells (CSCs) Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Cancer Stem Cells (CSCs) Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.3.1 North America Cancer Stem Cells (CSCs) Sales by Country 3.3.2 North America Cancer Stem Cells (CSCs) Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.4.1 Europe Cancer Stem Cells (CSCs) Sales by Country 3.4.2 Europe Cancer Stem Cells (CSCs) Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Cancer Stem Cells (CSCs) Market Facts & Figures by Region 3.5.1 Asia Pacific Cancer Stem Cells (CSCs) Sales by Region 3.5.2 Asia Pacific Cancer Stem Cells (CSCs) Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.6.1 Latin America Cancer Stem Cells (CSCs) Sales by Country 3.6.2 Latin America Cancer Stem Cells (CSCs) Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Cancer Stem Cells (CSCs) Market Facts & Figures by Country 3.7.1 Middle East and Africa Cancer Stem Cells (CSCs) Sales by Country 3.7.2 Middle East and Africa Cancer Stem Cells (CSCs) Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Cancer Stem Cells (CSCs) Historic Market Analysis by Type 4.1 Global Cancer Stem Cells (CSCs) Sales Market Share by Type (2015-2020) 4.2 Global Cancer Stem Cells (CSCs) Revenue Market Share by Type (2015-2020) 4.3 Global Cancer Stem Cells (CSCs) Price Market Share by Type (2015-2020) 4.4 Global Cancer Stem Cells (CSCs) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Cancer Stem Cells (CSCs) Historic Market Analysis by Application 5.1 Global Cancer Stem Cells (CSCs) Sales Market Share by Application (2015-2020) 5.2 Global Cancer Stem Cells (CSCs) Revenue Market Share by Application (2015-2020) 5.3 Global Cancer Stem Cells (CSCs) Price by Application (2015-2020) 6 Company Profiles and Key Figures in Cancer Stem Cells (CSCs) Business 6.1 Janssen 6.1.1 Corporation Information 6.1.2 Janssen Description, Business Overview and Total Revenue 6.1.3 Janssen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Janssen Products Offered 6.1.5 Janssen Recent Development 6.2 Qiagen 6.2.1 Qiagen Corporation Information 6.2.2 Qiagen Description, Business Overview and Total Revenue 6.2.3 Qiagen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Qiagen Products Offered 6.2.5 Qiagen Recent Development 6.3 Advanced Cell Diagnostics 6.3.1 Advanced Cell Diagnostics Corporation Information 6.3.2 Advanced Cell Diagnostics Description, Business Overview and Total Revenue 6.3.3 Advanced Cell Diagnostics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Advanced Cell Diagnostics Products Offered 6.3.5 Advanced Cell Diagnostics Recent Development 6.4 ApoCell 6.4.1 ApoCell Corporation Information 6.4.2 ApoCell Description, Business Overview and Total Revenue 6.4.3 ApoCell Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.4.4 ApoCell Products Offered 6.4.5 ApoCell Recent Development 6.5 Biofluidica 6.5.1 Biofluidica Corporation Information 6.5.2 Biofluidica Description, Business Overview and Total Revenue 6.5.3 Biofluidica Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Biofluidica Products Offered 6.5.5 Biofluidica Recent Development 6.6 Clearbridge Biomedics 6.6.1 Clearbridge Biomedics Corporation Information 6.6.2 Clearbridge Biomedics Description, Business Overview and Total Revenue 6.6.3 Clearbridge Biomedics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Clearbridge Biomedics Products Offered 6.6.5 Clearbridge Biomedics Recent Development 6.7 CytoTrack 6.6.1 CytoTrack Corporation Information 6.6.2 CytoTrack Description, Business Overview and Total Revenue 6.6.3 CytoTrack Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.4.4 CytoTrack Products Offered 6.7.5 CytoTrack Recent Development 6.8 Celsee 6.8.1 Celsee Corporation Information 6.8.2 Celsee Description, Business Overview and Total Revenue 6.8.3 Celsee Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Celsee Products Offered 6.8.5 Celsee Recent Development 6.9 Fluxion 6.9.1 Fluxion Corporation Information 6.9.2 Fluxion Description, Business Overview and Total Revenue 6.9.3 Fluxion Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.9.4 Fluxion Products Offered 6.9.5 Fluxion Recent Development 6.10 Gilupi 6.10.1 Gilupi Corporation Information 6.10.2 Gilupi Description, Business Overview and Total Revenue 6.10.3 Gilupi Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.10.4 Gilupi Products Offered 6.10.5 Gilupi Recent Development 6.11 Cynvenio 6.11.1 Cynvenio Corporation Information 6.11.2 Cynvenio Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.11.3 Cynvenio Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.11.4 Cynvenio Products Offered 6.11.5 Cynvenio Recent Development 6.12 On-chip 6.12.1 On-chip Corporation Information 6.12.2 On-chip Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.12.3 On-chip Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.12.4 On-chip Products Offered 6.12.5 On-chip Recent Development 6.13 YZY Bio 6.13.1 YZY Bio Corporation Information 6.13.2 YZY Bio Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.13.3 YZY Bio Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.13.4 YZY Bio Products Offered 6.13.5 YZY Bio Recent Development 6.14 BioView 6.14.1 BioView Corporation Information 6.14.2 BioView Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.14.3 BioView Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.14.4 BioView Products Offered 6.14.5 BioView Recent Development 6.15 Creatv MicroTech 6.15.1 Creatv MicroTech Corporation Information 6.15.2 Creatv MicroTech Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.15.3 Creatv MicroTech Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.15.4 Creatv MicroTech Products Offered 6.15.5 Creatv MicroTech Recent Development 6.16 Fluidigm 6.16.1 Fluidigm Corporation Information 6.16.2 Fluidigm Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.16.3 Fluidigm Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.16.4 Fluidigm Products Offered 6.16.5 Fluidigm Recent Development 6.17 Ikonisys 6.17.1 Ikonisys Corporation Information 6.17.2 Ikonisys Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.17.3 Ikonisys Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.17.4 Ikonisys Products Offered 6.17.5 Ikonisys Recent Development 6.18 AdnaGen 6.18.1 AdnaGen Corporation Information 6.18.2 AdnaGen Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.18.3 AdnaGen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.18.4 AdnaGen Products Offered 6.18.5 AdnaGen Recent Development 6.19 IVDiagnostics 6.19.1 IVDiagnostics Corporation Information 6.19.2 IVDiagnostics Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.19.3 IVDiagnostics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.19.4 IVDiagnostics Products Offered 6.19.5 IVDiagnostics Recent Development 6.20 Miltenyi Biotec 6.20.1 Miltenyi Biotec Corporation Information 6.20.2 Miltenyi Biotec Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.20.3 Miltenyi Biotec Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.20.4 Miltenyi Biotec Products Offered 6.20.5 Miltenyi Biotec Recent Development 6.21 Aviva Biosciences Corporation 6.21.1 Aviva Biosciences Corporation Corporation Information 6.21.2 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.21.3 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.21.4 Aviva Biosciences Corporation Products Offered 6.21.5 Aviva Biosciences Corporation Recent Development 6.22 ScreenCell 6.22.1 ScreenCell Corporation Information 6.22.2 ScreenCell Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.22.3 ScreenCell Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.22.4 ScreenCell Products Offered 6.22.5 ScreenCell Recent Development 6.23 Silicon Biosystems 6.23.1 Silicon Biosystems Corporation Information 6.23.2 Silicon Biosystems Cancer Stem Cells (CSCs) Description, Business Overview and Total Revenue 6.23.3 Silicon Biosystems Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2015-2020) 6.23.4 Silicon Biosystems Products Offered 6.23.5 Silicon Biosystems Recent Development 7 Cancer Stem Cells (CSCs) Manufacturing Cost Analysis 7.1 Cancer Stem Cells (CSCs) Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Cancer Stem Cells (CSCs) 7.4 Cancer Stem Cells (CSCs) Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Cancer Stem Cells (CSCs) Distributors List 8.3 Cancer Stem Cells (CSCs) Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast 10.1 Global Cancer Stem Cells (CSCs) Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Cancer Stem Cells (CSCs) by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Cancer Stem Cells (CSCs) by Type (2021-2026) 10.2 Cancer Stem Cells (CSCs) Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Cancer Stem Cells (CSCs) by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Cancer Stem Cells (CSCs) by Application (2021-2026) 10.3 Cancer Stem Cells (CSCs) Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Cancer Stem Cells (CSCs) by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Cancer Stem Cells (CSCs) by Region (2021-2026) 10.4 North America Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.5 Europe Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.6 Asia Pacific Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.7 Latin America Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 10.8 Middle East and Africa Cancer Stem Cells (CSCs) Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Trending Now: Cancer Stem Cells (CSCs) Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026| Janssen, Qiagen, Advanced Cell...

$30+ Billion Cell Expansion Market by Product, Cell Type, Application, End-user and Region – Forecast to 2025 – ResearchAndMarkets.com – Yahoo Finance

The "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global cell expansion market is projected to reach USD 30.06 billion by 2025 from an estimated USD 14.91 billion in 2020, at a CAGR of 15.1%.

The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users). The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Increasing incidence of chronic diseases and government investments for cell-based research are set to drive the cell expansion market

Growth in this market is largely driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities. On the other hand, ethical concerns regarding research in cell biology are expected to limit market growth to a certain extent in the coming years.

By instruments type, the cell expansion supporting equipment accounted for the fasted growing product segment of the cell expansion market

The instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems. The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment. They are used in cell culture processes for isolating, culturing, scaling-up, and extracting biological products. These instruments are essential in laboratories and institutes for conducting research and analyzing the cell structure and function for cell therapy research.

By cell type, the human cells segment accounted for the largest share of the cell expansion market

Based on cell type, the cell expansion market is segmented into human cells and animal cells. The human cells segment includes stem cells and differentiated cells. The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. The human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

Asia Pacific: The fastest-growing region in the cell expansion market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing focus of players on emerging Asian markets, increasing incidence of chronic and infectious diseases, rising geriatric population, and government initiatives for infrastructural improvements of healthcare facilities are driving the growth of the cell expansion market in this region.

North America: the largest share of the cell expansion market

North America accounted for the largest share of the cell expansion market. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

Company Profiles

Established Companies

Start-up Companies

For more information about this report visit https://www.researchandmarkets.com/r/y35ufs

View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005450/en/

Contacts

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Follow this link:
$30+ Billion Cell Expansion Market by Product, Cell Type, Application, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com - Yahoo Finance

Family need to raise 120K by September for lifesaving treatment for 11-year-old – Cheshire Live

The family of a brave 11-year-old Wistaston boy needs to raise 120,000 by September so he can have lifesaving treatment in Asia to stop a rare form of bone cancer returning.

Georgy Capener was diagnosed with the highly malignant Ewings Sarcoma after a fall in a friends back garden on Easter Sunday in 2018.

Since then the plucky Wistaston Church Lane pupil has undergone numerous rounds of high dose aggressive chemotherapy and radiotherapy.

As a result of the treatment he lost his right arm which has been replaced a titanium prosthesis.

Georgy went into remission in March of last year and life returned to a semblance of normality for the Crewe boy, his mum Helen, dad Richard, and sisters Ellie, 18, and Chloe, 13.

But in April this year the family were dealt another devastating blow when they learned the cancer had returned - this time in Georgys left sinus, just under his eye socket and in the back of his nose.

Helen told CheshireLive: Everything had been going really well and then there was the impact of the coronavirus pandemic so one scan [to check Georgy] was moved further on but we never got to it because he started having really painful headaches. I knew something wasnt right.

Georgys parents were told that, because of the location of the tumour, there was a chance he could lose his eyesight or suffer a stroke during the biopsy he needed.

Helen told how, at first, she didnt want him to have the biopsy, but she knew he had to.

We didnt know if he was going to come out with his eyesight or have a stroke but he came through it, she said. Hes so brave, hes been so brave throughout.

Georgy, who is a passionate Liverpool fan, is now undergoing chemotherapy and radiotherapy again.

The tumour cannot be removed surgically because of its location.

But the vital stem cell therapy which is essential to ensure he can live a normal, healthy life and prevent the cancer returning at a later stage costs 130,000 and is not available for Georgy on the NHS.

Helen said: After lengthy discussions with a stem cell transplant hospital in a top medical treatment centre in Thailand, we are thrilled that they are willing to accept Georgy.

The transplant will involve removing the faulty mother cell and harvesting new purified cells from a donated umbilical cord into his body to stop the cancer from returning. These procedures have very high success rates.

Georgy is due to finish his sixth and final round of chemotherapy at the beginning of September.

For the stem cell treatment to be successful the procedure would have to start immediately after that to ensure the cancer doesnt return straight away.

The family has set up a JustGiving appeal to raise the funds needed to save their little boys life. They need to raise 120,000 by the beginning of September.

Helen said: We set it up in the hope that we can raise some of this amount to help save our sons life. It is our only realistic option and, for the first time in a long time, we can be positive and see some sort of future.

If you can help please donate by visiting JustGiving here.

See the original post:
Family need to raise 120K by September for lifesaving treatment for 11-year-old - Cheshire Live

R3 Stem Cell International Now Offering Four Joint Injections for Only $3950 in Mexico – PR Web

Four Stem Cell Joint Injections for Only $3950! (888) 988-0515

SCOTTSDALE, Ariz. (PRWEB) July 29, 2020

R3 Stem Cell International is now offering patients the opportunity to receive four stem cell joint injections for only $3950. With 50 million stem cells total, patients may choose which extremities they would like treated.

Several studies have shown just how well stem cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with a long history of accreditation and pristine safety record. The lab abides by quality assurance standards that exceed those of the FDA.

Stem cell treatment for knees in Mexico at R3 works amazingly well. Patient satisfaction surveys at the center reveal that nine out of ten patients say they would have the procedure again and recommend it to friends and family.

According to R3 CEO David Greene, MD, MBA, "The biologics don't need preservative and viability exceeds 95%. The pureness and potency truly makes the difference in outcomes. Four joints for under $4000? What we put together for patients is incredible!"

The treatment process begins with a free phone consultation with one of R3's licensed, experienced stem cell doctors. Because the treatment includes 50 million stem cells, four joints may be included. The dedicated patient concierge representative assists with travel logistics. Travel from San Diego is included to the clinic, which is only 20 minutes from the San Diego airport.

Image guidance is used at the Center to ensure injection accuracy. In addition to arthritis treatment, R3 International offers stem cell treatment for autism, Lyme, COPD, kidney failure, neuropathy, diabetes, MS, ALS, stroke and much more.

Call (888) 988-0515 to learn more about therapies offered, and visit https://stemcelltreatmentclinic.com to read about the process.

Share article on social media or email:

The rest is here:
R3 Stem Cell International Now Offering Four Joint Injections for Only $3950 in Mexico - PR Web

Impact of COVID-19 on Cell Freezing Media for Cell Therapy Market Overview with Detailed Analysis, Competitive Landscape & Forecast To 2026 -…

Innovative Report on Cell Freezing Media for Cell Therapy Market with Competitive Analysis, New Business Developments, and Top Companies

A perfect mix of quantitative & qualitative Cell Freezing Media for Cell Therapy Market Market information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Cell Freezing Media for Cell Therapy Market. The study bridges the historical data from 2014 to 2019 and estimated until 2026.

Prominent players profiled in the study: BioLife Solutions, Akron Biotechnology, GE Healthcare, Thermo Fisher Scientific, Biological Industries, Merck, WAK-Chemie Medical, Zenoaq

Sample Report with Latest Industry Trends @https://www.acquiremarketresearch.com/sample-request/379423/

Covid-19 pandemic affects most industries in the globe. Here at acquire market research we offer you comprehensive data of related industry which will help and support your business in all possible ways.

This Report Provides an overview of the Cell Freezing Media for Cell Therapy market, containing global revenue, global production, sales, and CAGR. Also describe Cell Freezing Media for Cell Therapy product scope, market overview, market opportunities, market driving force, and market risks. The forecast and analysis of the Cell Freezing Media for Cell Therapy market by type, application, and region are also presented. The next part of the report provides a full-scale analysis of Cell Freezing Media for Cell Therapy competitive situation, sales, revenue and global market share of major players in the Cell Freezing Media for Cell Therapy industry. The basic information, as well as the profiles, applications, and specifications of products market performance along with Business Overview, are offered.

With FBS, Without FBS: With FBS, Without FBS

Application: Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation, Other

Geographical Regions: North America, Europe, Central & South America, Asia-Pacific, and the Middle East & Africa, etc.

Get Reasonable Discount on this Premium Report @https://www.acquiremarketresearch.com/discount-request/379423/

Scope of the Cell Freezing Media for Cell Therapy Report:

Worldwide Cell Freezing Media for Cell Therapy Market 2020, Market Size Value CAGR (XX %) and revenue (USD Million) for the historical years (2016 to 2019) and forecast years (2020 to 2026), with SWOT analysis, Industry Analysis, Demand, Sales, Market Drivers, Restraints, Opportunities and Forecast to 2026 cover in this research report.

As a part of our Corporate Social Responsibility, we would like to announce that we would be contributing 15 % of our profits to USA, UK, Italy, Spain and India relief fund.

This report covers the current scenario and growth prospects of the Cell Freezing Media for Cell Therapy Market for the period 2020-2026. The study is a professional and in-depth study with around tables and figures which provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the domain.

Finally, all aspects of the Global Cell Freezing Media for Cell Therapy Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and future prospects.

Browse Full [emailprotected] https://www.acquiremarketresearch.com/industry-reports/cell-freezing-media-for-cell-therapy-market/379423/

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach 555 Madison Avenue, 5th Floor, Manhattan, New York, 10022 USA Phone No.: +1 (800) 663-5579 Email ID: [emailprotected]

Here is the original post:
Impact of COVID-19 on Cell Freezing Media for Cell Therapy Market Overview with Detailed Analysis, Competitive Landscape & Forecast To 2026 -...

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – Business Wire

CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620) and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avactas neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics.

Respiratory diseases such as COVID-19 can cause serious damage to the lungs as a consequence of over-activation of the patient's immune system, resulting in cytokine release syndrome that can potentially lead to multiple organ failure and death. Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.

AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action.

The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease.

AffyXell will engineer mesenchymal stem cells to express SARS-COV-2 neutralising Affimer molecules in order to develop treatments for seriously ill COVID-19 patients, and will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.

Dr. Alastair Smith, Chief Executive of Avacta Group commented: I am very pleased to have extended our collaboration and license agreement with Daewoong Pharmaceutical to include the SARS-COV-2 neutralising Affimer molecules for the treatment of COVID-19 and to create the potential to respond very rapidly in future to global virus threats.

AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by COVID-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy.

More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as COVID-19.

I look forward to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, and on progress with our COVID-19 diagnostics programmes shortly.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, commented:

It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-COV-2 neutralising Affimer to be developed in combination with AffyXells cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.

Daewoong has been also conducting several research programs and clinical trial for COVID-19. As the COVID-19 crisis has caused great difficulties worldwide, we will continue to focus our efforts to develop a novel therapeutic agent for COVID-19.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

See the original post:
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy - Business Wire

FDA Approves New CAR-T Therapy for Mantle Cell Lymphoma – Cancer Health Treatment News

On July 24, the Food and Drug Administration (FDA) granted accelerated approval of a new CAR-T therapy, Tecartus (brexucabtagene autoleucel), for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment.

Tecartus (formerly known as KTE-X19), manufactured by Kite, a Gilead Company, is a living drug that reprograms a patients own T cells to fight cancer. About two thirds of participants treated in the ZUMA-2 study experienced complete remission, which in a majority of cases lasted at least a year.

"This approval is yet another example of customized treatments that use a patients own immune system to help fight cancer, Peter Marks, MD, PhD, director of the FDAs Center for Biologics Evaluation and Research, said in a press release. Were seeing continued advances in the field of gene therapy and remain committed to supporting innovation in this promising new area of medicine.

Mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkinlymphoma that involves overgrowth of abnormal B cells in lymph nodes. By the time it is diagnosed, MCL has often spread to the bone marrow and other organs, and it is frequently refractory (nonresponsive) to existing treatments or relapses following a period of remission.

Chimeric antigen receptor T-cell therapybetter known as CAR-Tinvolves removing a sample of a patients white blood cells, genetically reprogramming the T cells to recognize and attack their cancer, manufacturing a large number of the modified cells in a laboratory and infusing them back into the body. Like Kites previously approved CAR-T Yescarta (axicabtagene ciloleucel), Tecartus targets the CD19 protein on B cells, but the manufacturing process includes greater T-cell selection and lymphocyte enrichment.

The Phase II ZUMA-2 trial enrolled 74 adults with relapsed or refractory MCL in the United States and Europe who had previously tried up to five prior therapies. Six people ended up not receiving Tecartus because of manufacturing failures or death due to disease progression.

The primary analysis included 60 treated participants. Most were men, and the median age was 65. Most had Stage IV metastatic cancer, more than 80% had tried three or more prior treatments and 43% had received a bone marrow stem cell transplant.

A sample of the patients T cells were collected and modified, and they received strong conditioning chemotherapy to kill off some of their existing immune cells to make room for the new ones. They then received a single infusion of the genetically engineered cells.

As described at last years American Society of Hematology Annual Meeting and in The New England Journal of Medicine, the overall response rate, meaning complete or partial remission, was 93%, including 67% with complete responses. After a year of follow-up, 57% were still in remission, as were 43% of those followed for two years. The estimated one-year progression-free survival rate was 61%, and the estimated overall survival rate was 83%.

In a press release announcing the approval, Gilead/Kite gave an updated overall response rate of 87% and a complete response rate of 62%.

Therapies that receive FDA accelerated approval based on overall response rates are expected to undergo further testing in larger trials to confirm clinical benefits, and the agencycan rescind approval if they do not measure up. Tecartus is also currently in Phase I/II trials for acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Treatment with Tecartus was generally safe. The most common severe adverse events were low blood cell counts due to the conditioning chemotherapy and infections. Introducing engineered T cells can trigger a strong immune reaction known as cytokine release syndrome (CRS), which can lead to falling blood pressure and organ failure. As previously reported, 15% of study participants experienced Grade 3 or higher CRS, and 31% developed severe neurological side effects. Based on a larger group of patients, Gilead/Kite updated these figures to 18% and 37%, respectively. These side effects were managed with corticosteroids or Actemra (tocilizumab), and none were fatal.

A risk evaluation and mitigation strategy (REMS) for Tecartus has been approved by the FDA and combined with the YescartaREMS (www.YescartaTecartusREMS.com). This program informs health care professionals about the risks associated with CAR-T therapy and how to manage it.

Tecartus will be produced at Kites commercial manufacturing facility in El Segundo, California. The median turnaround time from T-cell collection to administration of the modified cells is around 15 days, according to the press release. The Kite Konnectprogram offers financial and logistical support for eligible patients receiving Tecartus or Yescarta.

Despite promising advances, there are still major gaps in treatment for patients with MCL who progress following initial therapy, ZUMA-2 lead investigator Michael Wang, MD, of University of Texas MD Anderson Cancer Center, said in the press release. Many patients have high-risk disease and are more likely to keep progressing, even after subsequent treatments. The availability of Tecartus as the first-ever cell therapy for patients with relapsed/refractory MCL provides an important option with a response rate of nearly 90% and early clinical evidence suggesting durable remissions in later lines of therapy.

Click here to learn more about lymphoma.

Original post:
FDA Approves New CAR-T Therapy for Mantle Cell Lymphoma - Cancer Health Treatment News

R3 Stem Cell International Now Offering Four Joint Injections for Only $3950 in Mexico – Benzinga

SCOTTSDALE, Ariz., July 29, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering patients the opportunity to receive four stem cell joint injections for only $3950. With 50 million stem cells total, patients may choose which extremities they would like treated.

Several studies have shown just how well stem cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with a long history of accreditation and pristine safety record. The lab abides by quality assurance standards that exceed those of the FDA.

Stem cell treatment for knees in Mexico at R3 works amazingly well. Patient satisfaction surveys at the center reveal that nine out of ten patients say they would have the procedure again and recommend it to friends and family.

According to R3 CEO David Greene, MD, MBA, "The biologics don't need preservative and viability exceeds 95%. The pureness and potency truly makes the difference in outcomes. Four joints for under $4000? What we put together for patients is incredible!"

The treatment process begins with a free phone consultation with one of R3's licensed, experienced stem cell doctors. Because the treatment includes 50 million stem cells, four joints may be included. The dedicated patient concierge representative assists with travel logistics. Travel from San Diego is included to the clinic, which is only 20 minutes from the San Diego airport.

Image guidance is used at the Center to ensure injection accuracy. In addition to arthritis treatment, R3 International offers stem cell treatment for autism, Lyme, COPD, kidney failure, neuropathy, diabetes, MS, ALS, stroke and much more.

Call (888) 988-0515 to learn more about therapies offered, and visit https://stemcelltreatmentclinic.com to read about the process.

SOURCE R3 Stem Cell International

See the rest here:
R3 Stem Cell International Now Offering Four Joint Injections for Only $3950 in Mexico - Benzinga

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Bulletin Line

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025). The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the Stem Cell Therapy market with current and future trends.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/691

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Stem Cell Therapy market. The study report covers all the recent developments and innovations in the market for a Stem Cell Therapy. The global keyword market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The research report on global Stem Cell Therapy market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Stem Cell Therapy market. Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

For Any Query on the Stem Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Continue reading here:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Bulletin Line

Advances in Treating Non-Small Cell Lung Cancer – GlobeNewswire

July 28, 2020 17:09 ET | Source: Family Features

photo-release

Photo courtesy of Getty Images

MISSION, Kan., July 28, 2020 (GLOBE NEWSWIRE) -- (Family Features) Despite progress in treating lung cancer, it is the leading cause of cancer deaths and impacts communities across the United States. The most common form of lung cancer is non-small cell lung cancer (NSCLC). NSCLC is a complex disease that can be challenging to treat, which may feel overwhelming and unsettling for people facing the disease.

Advanced lung cancer is devastating, so the fact that additional treatment options are now available that have the potential to extend the lives of patients gives us hope, said Bonnie J. Addario, lung cancer survivor and co-founder and chair, GO2 Foundation. Its exciting that this is a combination of immunotherapies, which brings a whole new approach for patients and physicians to consider when discussing treatment options.

A Chemo-Free Treatment Option A first-of-its-kind, chemotherapy-free treatment option was recently approved by the U.S. Food and Drug Administration as a first treatment for certain adults with advanced NSCLC, or NSCLC that has spread to other parts of the body. This treatment is a prescription medicine that is a combination of two immunotherapies, Opdivo (nivolumab) and Yervoy (ipilimumab), and it can be used for adults newly diagnosed with advanced NSCLC that tests positive for PD-L1 but do not have an abnormal EGFR or ALK gene.

Opdivo can cause problems that can sometimes become serious or life threatening and can lead to death. Serious side effects may include lung problems (pneumonitis); intestinal problems (colitis) that can lead to tears or holes in your intestine; liver problems (hepatitis); hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas); kidney problems, including nephritis and kidney failure; skin problems; inflammation of the brain (encephalitis); problems in other organs; severe infusion reactions; and complications of stem-cell transplant that uses donor stem cells (allogeneic). Additional serious side effects of Yervoy alone include: nerve problems that can lead to paralysis; eye problems; and complications of stem-cell transplant that uses donor stem cells (allogeneic). Please see Important Facts about side effects for Opdivo and Yervoy below.

The Chance for a Longer Life In a study of 793 previously untreated patients whose tumors tested positive for PD-L1, 396 were given the immunotherapy combination of Opdivo + Yervoy and 397 were given platinum-based chemotherapy. Treatment with the immunotherapy combination reduced the risk of death by 21%, with half of patients treated with the immunotherapy combination still alive at 17.1 months and half of patients treated with platinum-based chemotherapy still alive at 14.9 months. This analysis was conducted at a minimum follow-up of 29.3 months.

In additional analyses, 63% of patients treated withthe immunotherapy combinationand 56% treated with platinum-based chemotherapy were alive at one year, and 40% and 33% at two years, respectively.At three years, 33% of patients treated withthe immunotherapy combination and 22% of those treated with platinum-based chemotherapy were still alive. The analysis at these time points was not designed to show a difference between Opdivo + Yervoy and platinum-based chemotherapy.

The most common side effects of OPDIVO, when used in combination with YERVOY, include: feeling tired; diarrhea; rash; itching; nausea; pain in muscles, bones, and joints; fever; cough; decreased appetite; vomiting; stomach-area (abdominal) pain; shortness of breath; upper respiratory tract infection; headache; low thyroid hormone levels (hypothyroidism); decreased weight; and dizziness. The most common side effects of YERVOY include: feeling tired; diarrhea; nausea; itching; rash; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep. Please see Important Facts about side effects for Opdivo and Yervoy below.

As an oncologist who treats patients facing this particularly challenging disease, the fact that Opdivo plus Yervoy has shown overall survival at three years is important, said Hossein Borghaei, D.O., chief of thoracic medical oncology division at Fox Chase Cancer Center and an investigator in the clinical study.

Being diagnosed with lung cancer can be challenging and life-changing. Advancements in NSCLC bring additional treatment options that may enable certain patients a chance to live longer lives.

For more information, visit Opdivo.com or talk to you doctor about treatment options.

INDICATION Opdivo (nivolumab) is a prescription medicine used in combination with Yervoy (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.

It is not known if OPDIVO is safe and effective in children younger than 18 years of age.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

IMPORTANTSAFETYINFORMATION forOPDIVO(nivolumab) + YERVOY(ipilimumab)

OPDIVO is a medicine that may treat certain cancers by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when OPDIVO is used in combination with YERVOY.

YERVOY can cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment.

Serious side effects may include:

Additional serious side effects observed during a separate study of YERVOY alone include:

Get medical help immediatelyif you develop any of these symptoms or they get worse. It may keep these problems from becoming more serious. Your healthcare team will check you for side effects during treatment and may treat you with corticosteroid or hormone replacement medicines. If you have a serious side effect, your healthcare team may also need to delay or completely stop your treatment.

OPDIVO and OPDIVO + YERVOY can cause serious side effects, including:

Pregnancy and Nursing:

Tell your healthcare provider about:

The most common side effects of OPDIVO, when used in combination with YERVOY, include: feeling tired; diarrhea; rash; itching; nausea; pain in muscles, bones, and joints; fever; cough; decreased appetite; vomiting; stomach-area (abdominal) pain; shortness of breath; upper respiratory tract infection;headache; low thyroid hormone levels (hypothyroidism); decreased weight; and dizziness.

These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatch or call 1-800-FDA-1088.

Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO and YERVOY.

Michael French mfrench@familyfeatures.com 1-888-824-3337 editors.familyfeatures.com

About Family Features Editorial Syndicate A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c174110-3d0e-4a76-a2bc-46e0ebc4e6a5

See the original post:
Advances in Treating Non-Small Cell Lung Cancer - GlobeNewswire